Jerome Carpenter

Jerome Carpenter

Auto-generated profile, based on publicly available information

Jerome Carpenter

Marsico Lung Institute, University of North Carolina, Chapel Hill, North Carolina, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
JCJerome Carpenter
Jerome Carpenter
YWYang Wang
Yang Wang
RGRicha Gupta
Richa Gupta
YLYuanli Li
Yuanli Li
PHPrashamsha Haridass
Prashamsha Haridass
MKMehmet Kesimer
Mehmet Kesimer
Significance: Gel-forming mucins, MUC5AC and MUC5B, are the essential components of the protective mucus layer of the lungs. MUC5B is crucial for lung innate defense, and MUC5AC is generally secreted disproportionately in response to cigarette smoke and allergens. MUC5AC’s role in airway defense and chronic airway disease pathogenesis and how this emerges from its macromolecular assembly/gel-making properties are not known. We demonstrate MUC5AC binds significantly more to hydrophobic surfaces and forms stiffer and more viscoelastic layers compared to MUC5B. Also, MUC5AC forms higher-order oligomers in addition to dimers. These observations may generate insight into why/how MUC5AC forms a stagnant, “tethered” mucus layer in muco-obstructive lung diseases and could guide the development of strategies to intervene with more effective therapeutic agents.

12 June 2024 in mBio
Verified
Journal Article
Open access
MGMatthew A Greenwald
Matthew A Greenwald
SMSuzanne L. Meinig
Suzanne L. Meinig
LPLucas M. Plott
Lucas M. Plott
CRCristian Roca
Cristian Roca
MHMatthew G. Higgs
Matthew G. Higgs
MWMatthew C Wolfgang
Matthew C Wolfgang
The airway milieu of individuals with muco-obstructive airway diseases (MADs) is defined by the accumulation of dehydrated mucus due to hyperabsorption of airway surface liquid and defective mucociliary clearance. Pathological mucus becomes progressively more viscous with age and disease severity due to the concentration and overproduction of mucin and accumulation of host-derived extracellular DNA (eDNA). Respiratory mucus of MADs provides a niche for recurrent and persistent colonization by respiratory pathogens, including Pseudomonas aeruginosa , which is responsible for the majority of morbidity and mortality in MADs. Despite high concentration inhaled antibiotic therapies and the absence of antibiotic resistance, antipseudomonal treatment failure in MADs remains a significant clinical challenge. Understanding the drivers of antibiotic tolerance is essential for developing more effective treatments that eradicate persistent infections. The complex and dynamic environment of diseased airways makes it difficult to model antibiotic efficacy in vitro . We aimed to understand how mucin and eDNA concentrations, the two dominant polymers in respiratory mucus, alter the antibiotic tolerance of P. aeruginosa . Our results demonstrate that polymer concentration and molecular weight affect P. aeruginosa survival post antibiotic challenge. Polymer-driven antibiotic tolerance was not explicitly associated with reduced antibiotic diffusion. Lastly, we established a robust and standardized in vitro model for recapitulating the ex vivo antibiotic tolerance of P. aeruginosa observed in expectorated sputum across age, underlying MAD etiology, and disease severity, which revealed the inherent variability in intrinsic antibiotic tolerance of host-evolved P. aeruginosa populations. IMPORTANCE: Antibiotic treatment failure in Pseudomonas aeruginosa chronic lung infections is associated with increased morbidity and mortality, illustrating the clinical challenge of bacterial infection control. Understanding the underlying infection environment, as well as the host and bacterial factors driving antibiotic tolerance and the ability to accurately recapitulate these factors in vitro , is crucial for improving antibiotic treatment outcomes. Here, we demonstrate that increasing concentration and molecular weight of mucin and host eDNA drive increased antibiotic tolerance to tobramycin. Through systematic testing and modeling, we identified a biologically relevant in vitro condition that recapitulates antibiotic tolerance observed in ex vivo treated sputum. Ultimately, this study revealed a dominant effect of in vivo evolved bacterial populations in defining inter-subject ex vivo antibiotic tolerance and establishes a robust and translatable in vitro model for therapeutic development.